Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 2/20 | 0.56 |
| ▸ | FDPS | P14324 | 2/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888055 | 0.91 | NFE2L2 (0.56) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL18079018 | 0.91 | NFE2L2 (0.56) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL18569889 | 0.88 | NFE2L2 (0.61) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL28797908 | 0.88 | NFE2L2 (0.61) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL16621582 | 0.86 | NFE2L2 (0.59) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9974196 | 0.86 | APP (0.61) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL9974139 | 0.86 | NFE2L2 (0.66) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL18570134 | 0.85 | NFE2L2 (0.62) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL18079046 | 0.85 | APP (0.60) | NFE2L2KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL21156516 | 0.84 | NFE2L2 (0.60) | NFE2L2KDM4EALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993165-B1 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | ALLIANZ PHARMASCIENCE LTD (TW) | 2018-06-27 | — | — | EP | disclosed |
| EP-2993165-A2 | COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF | Allianz Pharmascience Ltd (TW) | 2016-03-09 | — | — | EP | disclosed |
| US-8202905-B2 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | ANDROSCIENCE CORPORATION (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2010-11-18 | — | — | US | disclosed |
| US-20090035362-A1 | Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss | ANDROSCIENCE CORPORATION | 2009-02-05 | — | — | US | disclosed |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292342-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | NFE2L2 73/4885KDM4E 484/4885ALDH1A1 112/4885 |
| US-20080188557-A1 | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof | AR, CYP17A1, CYP19A1 | NFE2L2 73/4885KDM4E 484/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.